知识人焦点 知识人关注 海归学子 学子园地 知识人论坛 知识人网址
智能监控平台 IPTV远程培训系统 智能卡解决方案 B2B电子金融解决方案
公司新闻 行业新闻

当前位置:知识人网>> 博士后之家>> 国外博士后招聘>>正文内容

挪威北极大学药学系系统药理学方向博士后
文章来源:知识人网整理       更新时间:2017年09月26日

Postdoc and PhD/Postdoc in two EU consortia

Job description

Two positions, one 3-year postdoc (EU consortium anTBiotic) and one 3-year postdoc or PhD student (JPI-AMR consortium Collateral Damage) position, are available immediately in the Systems Pharmacology group of Dr. Pia Abel zur Wiesch. The position is affiliated with the Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership Molecular Medicine and is located at the University of Tromsø, Norway. While the primary location is in Tromsø, the candidates have the option to visit international collaborators in industry and leading universities.
 

About the group

The Systems-Pharmacology group is headed by Dr. Abel zur Wiesch, Tenure Track Associate Professor at UiT, NCMM Young Associate Investigator and Visiting Assistant Professor at Yale School of Public Health. The aim of our work is to improve therapy in infectious diseases by using mathematical models to predict how much drug a patient should receive and how long and how often the patient should be treated. Our mathematical models describe both the intracellular reaction kinetics of drug-target binding as well as growth and death of populations of bacterial or cancer cells (Abel zur Wiesch & al., Science Transl. Med. 2015, Abel zur Wiesch et al., PLOS Computational Biology). We collaborate closely with experimentalists and clinicians. Two examples of on-going projects are:

anTBiotic
Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case.

The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB.
More specifically, the proposed studies aim to:

  • Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate;
  • Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application; and
  • Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB.

The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT).

These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used.

Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide.

扫一扫知识人网官方微信订阅号,更多最新学术资讯、博士后招聘信息 一手掌握!国外博士后、访问学者申请免费专业评估,专家答疑解惑,一键关注离世界顶尖大学一步之遥!

快速申请国外博士后(免费评估)


点击这里快速申请国外博士后

点击这里快速申请国外访问学者

知识人网拥有10余年专职国外博士后、访问学者职位服务经验;
世界30000多所大学、研究机构职位机会,学术研究职位专业服务机构;
资深专业顾问将竭诚为博士精英们提供最优质的服务,实现您梦想的阶梯;
全国免费电话欢迎垂询:4000-600-668 直拨电话:010-68228237/68161776/68227792/68168664